Yunnan Jianzhijia Health-Chain Co Ltd (605266) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Yunnan Jianzhijia Health-Chain Co Ltd stock ¥22.91, price ¥13.19, upside +73.7%, quality 54 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ¥13.19 – ¥61.52 · fair‑value band ¥16.04 – ¥29.78 · the ¥13.19 price screens below the ¥22.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Yunnan Jianzhijia Health-Chain Co in your weekly email
Every Wednesday you see whether Yunnan Jianzhijia Health-Chain Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jianzhijia Pharmaceutical Chain Group Co., Ltd. engages in the pharmaceutical retail business in China.
Show moreShow less
The company offers pharmaceuticals, health foods, personal care products, household health products, convenience foods, and daily consumables through offline community professional pharmacies, convenience stores, community clinics, Chinese medicine clinics, and physical examination centers in both online and offline ways.
The company was formerly known as Yunnan Jianzhijia Health-Chain Co., Ltd. and changed its name to Jianzhijia Pharmaceutical Chain Group Co., Ltd. in September 2022. Jianzhijia Pharmaceutical Chain Group Co., Ltd. was founded in 1998 and is based in Kunming, China.
Stock analysis
Yunnan Jianzhijia Health-Chain Co Ltd (605266) currently trades at ¥13.19, while our model-based Fair Value estimate is ¥22.91, implying the stock looks roughly 42% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥118.17 per share, and 24 of the 26 models we run sit above the ¥13.19 price.
Bear case: the Earnings-Based group reads lowest at ¥19.37, and 2 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥16.04 (bear) to ¥29.78 (bull), the price of ¥13.19 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Yunnan Jianzhijia Health-Chain Co Ltd reported revenue of 8.9B CNY in FY2025 versus 5.2B CNY in FY2021, a compound +14.3%/yr. Reported net income was 148M CNY in FY2025, compounding −16.2%/yr from FY2021.
Key figures
Market cap 2.0B CNY (≈ $304M) Small · P/E ratio 14.5 · P/S ratio 0.24 · EPS (TTM) ¥0.9100 · Dividend yield 9.6% · Net margin 1.5% · Return on equity 5.0% · Return on assets (EBIT) 4.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (medium confidence).
What moves the price
The share trades about 35% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 24% fair-value upside, at 74%, 605266 screens cheaper than that median.
Fair Value models
Bear¥16.04Fair Value ¥22.91Bull¥29.78
Price ¥13.19 · Upside +73.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−3.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Start year 2020 (pandemic). Over 10 years: +17.1% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+11.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.7%
Dividend (yield on the price)9.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.9% vs 18.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 5%
Compare Yunnan Jianzhijia Health-Chain Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside+73.7% · Top 25%
Profitability
Return on equity (12 months)5.0% · Below median
Return on assets1.5% · Below median
Net margin (12 months)1.5% · Below median
Operating margin (12 months)3.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)−3.3% · Bottom 25%
Dividend yield (12 months)9.6% · Top 25%
Balance sheet
Debt / equity0.36× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Yunnan Jianzhijia Health-Chain Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/605266
Frequently asked questions
Is Yunnan Jianzhijia Health-Chain Co Ltd (605266) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ¥22.91 versus a price of ¥13.19, about +74% upside (undervalued).
What is the fair value of 605266?
Our model-based fair value for Yunnan Jianzhijia Health-Chain Co Ltd is ¥22.91 (as of Nov 8, 2026), built from audited fundamentals. The current price: ¥13.19.
What is the quality score of 605266?
Yunnan Jianzhijia Health-Chain Co Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
Our model-based price target is the fair value of ¥22.91 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario ¥16.04, optimistic scenario ¥29.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Yunnan Jianzhijia Health-Chain Co Ltd stock forecast for 2026?
Our models put fair value at ¥22.91, about +74% upside versus a price of ¥13.19 (undervalued). Cautious scenario ¥16.04, optimistic scenario ¥29.78. The calculation is refreshed regularly with new filings.
What is the revenue of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
Yunnan Jianzhijia Health-Chain Co Ltd reported trailing-twelve-month revenue of about 8.6B CNY (latest available figure, as of Nov 8, 2026).
Does Yunnan Jianzhijia Health-Chain Co Ltd pay a dividend?
Yunnan Jianzhijia Health-Chain Co Ltd currently shows a dividend yield of 9.63% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Yunnan Jianzhijia Health-Chain Co Ltd (605266) and when is the ex-dividend date?
Yunnan Jianzhijia Health-Chain Co Ltd pays a dividend of ¥1.27 per share a year, a dividend yield of 9.6%. The last ex-dividend date was Jun 12, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 140% of earnings. Free cash flow covers the dividend 5.22 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What is the intrinsic value of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yunnan Jianzhijia Health-Chain Co Ltd it is ¥22.91 per share (as of Nov 8, 2026), against a price of ¥13.19. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Yunnan Jianzhijia Health-Chain Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 605266 trades below its calculated fair value: price ¥13.19, fair value ¥22.91, a gap of about +74% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 605266?
No. The price is what the market pays today (¥13.19); the fair value is what the company's own numbers justify (¥22.91). For Yunnan Jianzhijia Health-Chain Co Ltd the two are ¥9.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Yunnan Jianzhijia Health-Chain Co Ltd worth?
The market values Yunnan Jianzhijia Health-Chain Co Ltd at about 2.0B CNY (market capitalisation, as of Nov 8, 2026). Per share that is ¥13.19; our models calculate a fair value of ¥22.91 per share.
What do the bullish and bearish scenarios say about 605266?
Our models span a range for Yunnan Jianzhijia Health-Chain Co Ltd: cautious scenario ¥16.04, base ¥22.91, optimistic ¥29.78 per share (as of Nov 8, 2026, price ¥13.19). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 605266?
Yunnan Jianzhijia Health-Chain Co Ltd trades at a price-to-earnings ratio of 14.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥22.91 is built from several models across several years. Other multiples: P/B 0.8, P/S 0.2, EV/EBITDA 5.0.
How solid is the balance sheet of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
Balance-sheet figures for Yunnan Jianzhijia Health-Chain Co Ltd (as of Nov 8, 2026): return on equity 5.0%, debt of 0.36 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 605266 from its 52-week high?
Yunnan Jianzhijia Health-Chain Co Ltd trades at ¥13.19, about 35% below its 52-week high of ¥20.40 and at the low of ¥13.19 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥22.91 is for.
Which stocks are comparable to Yunnan Jianzhijia Health-Chain Co Ltd?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yunnan Jianzhijia Health-Chain Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price ¥13.19, calculated fair value ¥22.91 (+74%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 605266 calculated?
We run Yunnan Jianzhijia Health-Chain Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥22.91 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Yunnan Jianzhijia Health-Chain Co Ltd currently trades 42% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
The closing price on Nov 9, 2026 was ¥13.19. Our model-based fair value is ¥22.91, about +74% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yunnan Jianzhijia Health-Chain Co Ltd right now?
The price is below even our cautious bear case (¥16.04). The market is more pessimistic than our downside scenario. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (¥16.04 to ¥29.78) leaves room in how you read the outcome.
Where does the earnings growth of Yunnan Jianzhijia Health-Chain Co Ltd (605266) come from?
Earnings per share at Yunnan Jianzhijia Health-Chain Co Ltd grew +34.6 % a year from 2014 to 2024. Broken into its drivers: revenue per share +16.1 %, EBIT margin +14.7 %, tax rate +3.3 %, residual (interest, one-offs) −2.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Yunnan Jianzhijia Health-Chain Co Ltd
How large is the market capitalisation of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
The market capitalisation of Yunnan Jianzhijia Health-Chain Co Ltd is 2.0B CNY (≈ $304M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
The price-to-sales ratio of Yunnan Jianzhijia Health-Chain Co Ltd is 0.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
Earnings per share at Yunnan Jianzhijia Health-Chain Co Ltd are ¥0.9100 (price ÷ EPS = P/E 14.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
The dividend yield of Yunnan Jianzhijia Health-Chain Co Ltd is 9.6% (payout 140%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
The net margin of Yunnan Jianzhijia Health-Chain Co Ltd is 1.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
The return on equity (ROE) of Yunnan Jianzhijia Health-Chain Co Ltd is 5.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
On an EBIT basis the return on assets of Yunnan Jianzhijia Health-Chain Co Ltd is 4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
The operating margin of Yunnan Jianzhijia Health-Chain Co Ltd is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
Revenue at Yunnan Jianzhijia Health-Chain Co Ltd is growing −3.3% versus a year earlier (3y avg +5.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yunnan Jianzhijia Health-Chain Co Ltd (605266)?
Earnings per share at Yunnan Jianzhijia Health-Chain Co Ltd are growing −54.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yunnan Jianzhijia Health-Chain Co Ltd (605266) generate?
The free cash flow of Yunnan Jianzhijia Health-Chain Co Ltd is 1.0B CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Yunnan Jianzhijia Health-Chain Co Ltd (605266) carry?
The net debt of Yunnan Jianzhijia Health-Chain Co Ltd is 2.1B CNY (fiscal year 2025, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Yunnan Jianzhijia Health-Chain Co Ltd in the live analysis
One click puts Yunnan Jianzhijia Health-Chain Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026